Source: Assembly Biosciences
NEW YORK, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that Dr. Russell Ellison, Chairman and Chief Executive Officer, will be presenting at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13th at 1:30 p.m. Eastern Time at the Pierre Hotel in New York.
A live webcast and replay of the presentation will be available on the "Investors" section of the Company's website.
Ventrus is a development stage pharmaceutical company focused on the development of late-stage prescription drugs for gastrointestinal problems, specifically anal disorders. Our lead product is topical diltiazem (VEN 307) for the treatment of anal fissures for which the first Phase 3 trial was initiated in November 2010, and reported positive top line results in May 2012. The second Phase 3 trial began enrollment in the fourth quarter of 2012 and is ongoing and we estimate that it will be completed in the fourth quarter of 2013 and that we will file a 505b(2) New Drug Application with the Food and Drug Administration by the end of 2013 with a possible PDUFA date at the end of 2014. Our product candidate portfolio also includes a Phase 2 stage topical phenylephrine (VEN 308) intended to treat fecal incontinence in patients who have had a colectomy using the Ileal pouch anal anastomosis (IPAA) procedure. VEN 307 and VEN 308 are two molecules that were previously approved and marketed for other indications and that have been formulated into our in-licensed proprietary topical treatments for these new gastrointestinal indications.
Ventrus BioSciences, Inc. David Barrett 646-706-5208 email@example.com Argot Partners David Pitts 212-600-1902 firstname.lastname@example.org